checkAd

     224  0 Kommentare Victory Square Technologies Portfolio Company’s Leishmaniasis Rapid Test Receives Brazilian MAPA Approval for Sale & Use for the Country of Brazil and Enters into a Sales & Distribution Contract with Ecodiagnostica of Brazil - Seite 3

    Reference (2)
    PARASITOLOGY - CHAPTER TWO BLOOD AND TISSUE PROTOZOA PART 1 TRYPANOSOMIASIS AND LEISHMANIASIS
    Dr Abdul Ghaffar Professor Emeritus University of South Carolina http://www.microbiologybook.org

    On behalf of the board,

    Shafin Diamond Tejani
    Chief Executive Officer
    Victory Square Technologies

    For further information about the Company, please contact:

    Investor Relations Contact – Alex Tzilios
    Email: alexandros@victorysquare.com
    Telephone: 778-867-0482

    Media Relations Contact – Howard Blank, Director
    Email: howard@victorysquare.com
    Telephone: 604-928-6066

    ABOUT VICTORY SQUARE TECHNOLOGIES INC.

    Victory Square (VST) builds, acquires and invests in promising startups, then provides the senior leadership and resources needed to fast-track growth. The result: rapid scale-up and monetization, with a solid track record of public and private exits.

    VST's sweet spot is the cutting-edge tech that's shaping the 4th Industrial Revolution. Our portfolio consists of 20 global companies using AI, VR/AR and blockchain to disrupt sectors as diverse as fintech, insurance, health and gaming.

    What we do differently for startups
    VST isn't just another investor. With real skin in the game, we're committed to ensuring each company in our portfolio succeeds. Our secret sauce starts with selecting startups that have real solutions, not just ideas. We pair you with senior talent in product, engineering, customer acquisition and more. Then we let you do what you do best — build, innovate and disrupt. In 24-36 months, you'll scale and be ready to monetize.

    What we do differently for investors
    VST is a publicly-traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTCQX (VSQTF).

    For investors, we offer early-stage access to the next unicorns before they're unicorns.

    Our portfolio represents a uniquely liquid and secure way for investors to get access to the latest cutting-edge technologies. Because we focus on market-ready solutions that scale quickly, we're able to provide strong and stable returns while also tapping into emerging global trends with big upsides. For more information, please visit www.victorysquare.com.

    Forward Looking Statement

    This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the outlook of the business of Victory Square, including, without limitation, statements relating to future performance, execution of business strategy, future growth, business prospects and opportunities of Victory Square and its related subsidiaries, including Victory Square Health Inc., and other factors beyond our control. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, “continues”, “project”, “potential”, “possible”, “contemplate”, “seek”, “goal”, or similar expressions, or may employ such future or conditional verbs as “may”, “might”, “will”, “could”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements of historical facts contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

    Seite 3 von 4



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Victory Square Technologies Portfolio Company’s Leishmaniasis Rapid Test Receives Brazilian MAPA Approval for Sale & Use for the Country of Brazil and Enters into a Sales & Distribution Contract with Ecodiagnostica of Brazil - Seite 3 Victory Square Health’s Leishmaniasis Rapid Test received Brazilian MAPA approval for sale and usage in Brazil and export to Mercosur Countries in Central and South AmericaLeishmaniasis is a parasitic disease that affects humans and canines in …

    Schreibe Deinen Kommentar

    Disclaimer